Companies
Intel Misses Out on PlayStation 6 Chip Deal: A Setback to Its Foundry Ambitions
Failed Contract Highlights Competitive Pressures and Strategic Shifts In a bid to reinvigorate its struggling business, Intel Corporation (INTC) sought...
Unity Cancels Runtime Fee and Announces Subscription Price Increases: What It Means for Developers and Investors
Unity's decision to cancel the controversial runtime fee paves the way for Unity 6, while subscription price increases promise better...
EXCLUSIVE: MGM Resorts CEO Bill Hornbuckle on Growth, Strategy, and the Future of Hospitality
MGM Resorts, a leading global hospitality and entertainment company, continues to make strides in expanding its footprint, enhancing customer experience,...
Eli Lilly to Invest $1.8 Billion in Expanding Manufacturing for Alzheimer’s, Diabetes, and Obesity Treatments in Ireland
Major investments in Limerick and Kinsale will help meet soaring demand for key drugs Eli Lilly (LLY) has announced plans...
Boeing Workers Weigh Tentative Labor Agreement Amid Potential Strike
Union's 33,000 members to vote on deal offering 25% wage increase over four years as CEO Ortberg faces first major...
Tesla Poised to Reshape Multiple Industries: From Robotaxis to Humanoid Robots
An In-Depth Look at Tesla’s Vision for the Future of Technology Tesla (TSLA), widely known for revolutionizing the electric vehicle...
Cathie Wood’s Ark Invest Makes Bold Moves: Buys DraftKings, AMD, and Tempus AI; Sells Palantir and Unity
Key Investments Highlight Strategic Shifts in Tech and AI Focus Cathie Wood, CEO of Ark Invest and one of Wall...
JPMorgan Chase Shares Plunge as President Warns of Optimistic 2025 Projections
Inflation, Federal Reserve Policies, and Investment Challenges Impact Outlook JPMorgan Chase (JPM), the largest U.S. bank by assets, saw its...
Southwest Airlines Faces Leadership Shake-Up Amid Pressure from Activist Investor
Chairman Gary Kelly to Retire in 2025 as Elliott Investment Management Pushes for Changes Southwest Airlines (LUV) is set for...
Advancements in EGFR-Targeted Therapies: Promising Phase 1b Data for Firmonertinib in NSCLC Patients with Rare EGFR Mutations
Novel treatments show potential in addressing hard-to-treat mutations in lung cancer, bringing hope for improved outcomes ArriVent Biopharma recently unveiled...
